Cambium Bio
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Cambium Bio Limited (ASX: CMB) is a Sydney-based clinical-stage regenerative medicine company developing biologics for ophthalmology and tissue repair. Its proprietary technology is based on human platelet lysate; its lead product candidate, Elate Ocular, is being developed for dry eye disease and is advancing toward Phase 3 trials. Its stem cell platform Progenza is applied to therapies for knee osteoarthritis, and the company also manufactures stem cell growth supplements such as UltraGRO. The company was formerly named Regeneus Ltd and renamed Cambium Bio in April 2024 after merging with Cambium Medical Technologies LLC.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Regeneus era
Operated as Regeneus Ltd, a Sydney-based clinical-stage regenerative medicine company developing cell therapies including the Progenza stem cell platform.
- Merger with Cambium
Merged with Cambium Medical Technologies LLC; shareholder approval was granted on March 28, 2024 and the merger closed on April 5, 2024, adding the Elate Ocular program and royalty agreements with Emory University and Zheng Yang Biomedical Technology.
- Renamed and ASX-listed
Changed its name from Regeneus Ltd to Cambium Bio Limited and its ASX code from RGS to CMB; the company remains listed on the ASX and continues clinical development toward Phase 3 trials of Elate Ocular.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.